INTRODUCTION
Respiratory syncytial virus (RSV) is recognized as a major cause of severe disease in adults, particularly those having cardiorespiratory comorbidities or immunosuppression. The recent deployment of monoclonal antibodies targeting the prefusion F protein could be used in the future to prevent RSV-associate...
N. de Prost, M. Le Goff, P. Cappy et al.· Infectious Disease and Thera...· 0 citations
Chronic viral infections are ubiquitous in humans, with individuals carrying multiple viruses that can reactivate during physiological stress, including severe illness1. Notably, SARS-CoV-2 infection has been shown to reactivate chronic viruses such as Epstein–Barr virus and cytomegalovirus, yet the full extent, tempor...
Cole P. Maguire, Jing Chen, Nadine Rouphael et al.· Nature· 3 citations
The data show that complement potentiates the ability of antispike antibodies to neutralize immune-evasive SARS-CoV-2 variants and in sera from individuals with severe COVID-19, both complement-mediated neutralization and anti-S2 antibody levels were associated with improved survival.
M. Jungbauer-Groznica, Pierre Rosenbaum, I. Staropoli et al.· Science Translational Medici...· 1 citation
This study provides new resources concerning the SARS-CoV-2 variants circulating in West and Central Africa between 2020 and 2022, which are less represented in global datasets.
Guilbaud Romane, A. Maiga, A. Ouedraogo et al.· Journal of Infection and Pub...· 0 citations
Investigating how the vaccine shapes the CD4+ T cell immunity and how these responses cooperate in reducing the acquisition found that DV1 DNA/ALVAC/gp120 vaccine elicited envelope-specific immunomodulatory Tr1 CD4+ T cells, and that total Tr1 responses were associated with a reduced risk of viral acquisition.
Massimiliano Bissa, S. Fourati, Sohyoung Kim et al.· Journal of Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
